Anticancer Bioscience

[On Demand]
Anticancer Bioscience is a pre-clinical precision oncology company. We identify and exploit synthetic lethal approaches for the development of targeted cancer therapies with potential to be both safer and more effective. Advanced therapies in our pipeline attack cancers with MYC overexpression as a means to treat aggressive cancers with few therapeutic options. We plan to advance one MYC-synthetic lethal drug and a novel contact inhibition restoration therapy into clinical trials by the end of 2022.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
MYC-Synthetic lethal drugs
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
VP, Translational Biology
Anticancer Bioscience